Abstract:Background: Vaccination is recognized as the only practical measure for preventing Japanese encephalitis. Production shortage, costs, and issues of licensure impair vaccination programmes in many affected countries. Concerns over vaccine effectiveness and safety also have a negative impact on acceptance and uptake. Objectives: To evaluate vaccines for preventing Japanese encephalitis in terms of effectiveness, adverse events, and immunogenicity. Search strategy: In March 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE, EMBASE, LILACS, BIOSIS, and reference lists. We also attempted to contact corresponding authors and vaccine companies. Selection criteria: Randomized controlled trials (RCTs), including cluster-RCTs, comparing Japanese encephalitis vaccines with placebo (inert agent or unrelated vaccine), no intervention, or alternative Japanese encephalitis vaccine. Data collection and analysis: Authors independently extracted data and assessed methodological quality. Dichotomous data were compared with relative risks and a 95% confidence interval (CI), and converted into percentage vaccine efficacy. Main results: Eight RCTs involving 358,750 participants were included. These trials investigated two available and three pre-licensure vaccines. Two RCTs assessing efficacy of the commercially available inactivated Nakayama vaccine were identified. A two-dose schedule of the licensed vaccine provided significant protection of 95% (95% CI 10% to 100%) for one year only, while two doses of an unpurified precursor vaccine protected children by 81% (95% CI 45% to 94%) in year one and by 59% (95% CI 2% to 83%) in year two. Serious adverse events were not observed. Mild and moderate episodes of injection site soreness, fever, headache, and nausea were reported in less than 6% of children receiving inactivated vaccine compared to 0.6% of unvaccinated controls. One cluster-RCT compared the live-attenuated SA14-14-2 vaccine (widely used in China) with no intervention measuring adverse events. Fever was reported in 2.7% of vaccinees compared to 3.1% of controls, while 0.1% of both groups suffered diarrhoea or seizures. Four small pre-licensure RCTs assessing a genetically engineered vaccine and two cell culture-derived inactivated vaccines revealed high immunogenicity and relative safety. Authors' conclusions: Only one of the three currently used vaccines has been assessed for efficacy in a RCT. Other RCTs have assessed their safety, however, and they appear to cause only occasional mild or moderate adverse events. Further trials of effectiveness and safety are needed for the currently used vaccines, especially concerning dose levels and schedules. Trials investigating several new vaccines are planned or in progress.

Determination and Evaluation of the Qualities of Commercial Live Attenuated Vaccines of Japanese Encephalitis Produced in 2009-2011

Evaluation of Environment Safety of a Japanese Encephalitis Live Attenuated Vaccine.

A RELIABLE METHOD FOR DETERMNATION OF JAPANESE ENCEPHALITIS VIRUS TITERS

Safety and Minimum Immune Dose and Immune Potency Tests of Avian Encephalomyelitis Live Vaccines

Vaccines for preventing Japanese encephalitis

Novel envelope protein time-resolved fluoroimmunoassay as an alternative in vitro potency assay for quality control of inactivated Japanese encephalitis virus vaccine

Investigation of Immune Response Induction by Japanese Encephalitis Live‐attenuated and Chimeric Vaccines in Mice

Characterization and Phylogenetic Analysis of the Field Japanese Encephalitis Virus Strains Isolated from Seminal Fluid of Diseased Stock Boars

Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis

Vector Mosquito Ecology and Japanese Encephalitis Virus Genotype III Strain Detection from Culex tritaeniorhynchus and Pig in Huaihua, China.

Main Factors Influencing the Efficient Propagation of Virulent or Attenuated Strains of Japanese Encephalitis Virus in BHK-21 Cells

Establishment of the Indirect Immunofluorescence Assay for Detecting the IgG Antibody of Epidemic Encephalitis Virus in Serum of Pigs and Its Preliminary Use

Molecular Detection and Genetic Characterization of Japanese Encephalitis Virus in Animals from 11 Provinces in China

Epidemiology analysis of major viral diseases of porcine in Zhejiang province during 2008-2011

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Molecular characterization of infectious bronchitis virus in Southwestern China for the protective efficacy evaluation of four live vaccine strains

Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus

Study of the association of seventeen single nucleotide polymorphisms and their haplotypes in the TNF-α, IL-2, IL-4 and IL-10 genes with the antibody response to inactivated Japanese encephalitis vaccine

Japanese Encephalitis Virus Infection Rate and Detection of Genotype I from Culex Tritaeniorhynchus Collected from Jiangsu, China.

Efficacy of commercial live vaccines against QX-like infectious bronchitis virus in Japan

Natural products and derivatives as Japanese encephalitis virus antivirals